biostudies-literatureBisbee CSt. Jude Children&apos;s Research Hospital cancer center supportNational Cancer InstituteAmerican Lebanese Syrian Associated CharitiesNCI NIH HHS459-468https://www.ebi.ac.uk/biostudies/studies/S-EPMC8957602biostudies-literatureUnknown89(4)<h4>Purpose</h4>Crenolanib, an oral inhibitor of platelet-derived growth factor receptor, was evaluated to treat children and young adults with brain tumors. Crenolanib population pharmacokinetics and covariate influence were characterized in this patient population.<h4>Methods</h4>Patients enrolled on this phase I study (NCT01393912) received oral crenolanib once daily. Serial single-dose and steady-state serum pharmacokinetic samples were collected and analyzed using a validated LC-ESI-MS/MS method. Population modeling and covariate analysis evaluating demographics, laboratory values, and comedications were performed. The impact of significant covariates on crenolanib exposure was further explored using model simulations.<h4>Results</h4>Crenolanib serum concentrations were analyzed for 5Cancer chemotherapy and pharmacologyPopulation pharmacokinetics of crenolanib in children and young adults with brain tumors.PMC8957602P30 CA021765R25CA23944R25 CA023944R01CA154619CA21765Bisbee CCampagne OGajjar ATinkle CLStewart CFfalsePopulation pharmacokinetics of crenolanib in children and young adults with brain tumors.<h4>Purpose</h4>Crenolanib, an oral inhibitor of platelet-derived growth factor receptor, was evaluated to treat children and young adults with brain tumors. Crenolanib population pharmacokinetics and covariate influence were characterized in this patient population.<h4>Methods</h4>Patients enrolled on this phase I study (NCT01393912) received oral crenolanib once daily. Serial single-dose and steady-state serum pharmacokinetic samples were collected and analyzed using a validated LC-ESI-MS/MS method. Population modeling and covariate analysis evaluating demographics, laboratory values, and comedications were performed. The impact of significant covariates on crenolanib exposure was further explored using model simulations.<h4>Results</h4>Crenolanib serum concentrations were analyzed for 52022-01-01T00:00:00Z2022 Apr2025-04-26T04:42:58.314Z2025-04-06T11:14:56.376ZS-EPMC89576023521277910.1007/s00280-022-04412-8